|Bid||0.000 x 900|
|Ask||0.000 x 800|
|Day's Range||117.370 - 117.786|
|52 Week Range||99.230 - 118.060|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.08%|
In 2Q17, BioMarin Pharmaceuticals’ (BMRN) Aldurazyme generated revenues of around $20 million, which was a ~6% increase on a year-over-year (or YoY) basis.
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.
To expand Xyrem’s addressable market, JAZZ has been evaluating the efficacy of Xyrem in pediatric narcolepsy patients with cataplexy and excessive sleepiness.
Bioverativ (BIVV) plans to improve compliance rates for hemophilia patients further by launching therapies with lower dosage frequency.
Many of the largest exchange-traded funds focus on U.S. large-cap stocks. For example, the two largest ETFs, and three of the five biggest, track the S&P 500. While the S&P 500 is the benchmark U.S. equity ...